British manufacturers are asking the government to negotiate access to the single market and a form of customs union along with suitable transition period. The call comes from EEF, the
Tag "European Union"
GP leaders are warning that nearly 3.5 million patients are at risk of losing their family doctor, if the status of doctors from the European Union is not protected during
The European Commission has published the in vitro diagnostic medical device Regulation (IVDR) and the medical device Regulation (MDR). The next step is a transition period of three years for
On 4 May, the in vitro diagnostic medical device industry will gather in Dublin for an All-Ireland IVD Symposium on the new European regulation. Mani Subramani, head of business support,
EU regulators have expanded the scope of Janssen’s Darzalex to include patients with multiple myeloma who have received at least one prior therapy, when given in combination with lenalidomide and
The European Commission has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC). The
Now that the die has been cast, it’s time for the deal-making process to begin – if indeed a deal is on the cards. It seems that every time a
Xeljanz (tofacitinib citrate) receives marketing authorization in the European Union for the treatment of moderate to severe active rheumatoid arthritis (RA). Pfizer Inc. announced today that the European Commission (EC)
Frost & Sullivan, Gary Jeffery comments on the implications of Brexit for businesses both in and out of the UK. Theresa May set out an ambitious plan of maintaining a
Price rises in the EU stir Members of European Parliament to discuss ways to make medicines more affordable, including increasing clarity on R&D costs New medicine prices in the EU
29 – 31 March 2017, Glasgow, United Kingdom. DIA, (founded as the Drug Information Association) announced critical workshops to be held at the 2017 DIA EuroMeeting. The goal of the
Mundipharma is gearing up to launch biosimilar Truxima in seven European markets for the treatment of certain cancers and inflammatory conditions, after Celltrion bagged a regulatory approval for the drug.
Advertisements
